High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27313265.
- Also identified by DOI 10.1093/cid/ciw398.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.
Medical subject headings
- Anti-Bacterial Agents
- Azabicyclo Compounds
- Bacteremia
- Ceftazidime
- Enterobacteriaceae
- Enterobacteriaceae Infections